The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024.

On the same day the FDA signed off on Casgevy in sickle cell disease, the agency also approved bluebird bio’s cell-based gene therapy Lyfgenia (lovotibeglogene autotemcel). The company already ...

In December, the US Food and Drug Administration (FDA) approved the first two cell-based gene therapies for treating sickle ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program ...

Casgevy, developed with Vertex Pharmaceuticals ... Furthermore, Bluebird's Lyfgenia, which treats SCD, costs $3.1 million in the U.S. -- and comes with a warning for blood cancer.

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...